We are proud to announce the publication of our latest work in the Journal for ImmunoTherapy of Cancer (JITC): “Synthetic DNA vaccine platform elicits potent immunity where electroporated naked-mRNA is non-immunogenic” (read more)

The Liquid Biopsy Revolution: Insights from the 1st SIBIL Annual Meeting The 1st Annual Meeting of SIBIL (Società Italiana di Biopsia Liquida) was an extraordinary gathering of experts focused on a single goal: bringing non-invasive, real-time cancer monitoring into standard clinical practice. Liquid Biopsy is a game-changer for early detection and precision medicine (read more)

We’re heading to the Investival Showcase Conference in London. Our CEO Luigi Aurisicchio will be connecting with investors, partners and peers driving breakthroughs in personalized cancer vaccines with neoantigen prediction, synthetic DNA and innovative solutions for cancer patients. (read more)